{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-067544","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.210535+00:00","generated_at":"2026-06-01T06:45:06.660343+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ocular Therapeutix cuts 13% of workforce, 37 jobs, to prioritize AXPAXLI","bullets":["Board approved reduction in force of 37 employees (~13% of workforce), mainly in R&D and technical operations.","Action taken to focus resources on AXPAXLI (axitinib intravitreal implant) for wet AMD clinical development.","Expects total restructuring costs of $1.0 to $2.0 million for severance and related costs in Q2/Q3 2024.","Reduction expected to be substantially completed in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-067544","json":"https://secwatch.observer/filing/0001104659-24-067544.json","markdown":"https://secwatch.observer/filing/0001104659-24-067544.md","text":"https://secwatch.observer/filing/0001104659-24-067544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/0001104659-24-067544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924067544/tm2416236d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:45:06.660343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}